9,634 Shares in Bristol Myers Squibb Company $BMY Bought by Flatrock Wealth Partners LLC

Posted by Francis Steltz on Jul 8th, 2026

Flatrock Wealth Partners LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 9,634 shares of the biopharmaceutical company’s stock, valued at approximately $584,000.

Several other large investors have also recently made changes to their positions in BMY. Northwestern Mutual Investment Management Company LLC boosted its position in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after purchasing an additional 172 shares in the last quarter. KCM Investment Advisors LLC increased its position in Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 174 shares in the last quarter. Investment Research Partners LLC raised its stake in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 179 shares during the last quarter. ESG Planning DBA Harper Investing boosted its holdings in Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after acquiring an additional 180 shares in the last quarter. Finally, REAP Financial Group LLC grew its stake in shares of Bristol Myers Squibb by 26.1% in the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 182 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BMY has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. HSBC boosted their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday. Finally, UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

Get Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Stock Up 2.2%

BMY stock opened at $57.93 on Wednesday. The company has a market cap of $118.31 billion, a price-to-earnings ratio of 16.27, a P/E/G ratio of 0.16 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The business’s 50-day moving average is $56.84 and its two-hundred day moving average is $57.56. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.